Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

STREAM Study Collaborators

doi:10.1016/S0140-6736(22)02078-5

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

STREAM Study Collaborators

Mycobacteriology

Research output: Contribution to journal › A1: Web of Science-article › peer-review

Original language	English
Journal	Lancet
Volume	400
Issue number	10366
Pages (from-to)	1858-1868
Number of pages	11
ISSN	0140-6736
DOIs	https://doi.org/10.1016/S0140-6736(22)02078-5
Publication status	Published - 2022

Access to Document

10.1016/S0140-6736(22)02078-5Licence: CC BY

Cite this

@article{722847089b724dc7b72924784b5ababd,

title = "Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial",

author = "{STREAM Study Collaborators} and RL Goodall and SK Meredith and AJ Nunn and A Bayissa and AK Bhatnagar and G Bronson and CY Chiang and F Conradie and M Gurumurthy and B Kirenga and N Kiria and D Meressa and R Moodliar and G Narendran and N Ngubane and M Rassool and K Sanders and R Solanki and SB Squire and G Torrea and B Tsogt and E Tudor and {Van Deun}, A and ID Rusen",

note = "FTX; DOAJ; (CC BY)",

year = "2022",

doi = "10.1016/S0140-6736(22)02078-5",

language = "English",

volume = "400",

pages = "1858--1868",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10366",

}

TY - JOUR

T1 - Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

AU - STREAM Study Collaborators

AU - Goodall, RL

AU - Meredith, SK

AU - Nunn, AJ

AU - Bayissa, A

AU - Bhatnagar, AK

AU - Bronson, G

AU - Chiang, CY

AU - Conradie, F

AU - Gurumurthy, M

AU - Kirenga, B

AU - Kiria, N

AU - Meressa, D

AU - Moodliar, R

AU - Narendran, G

AU - Ngubane, N

AU - Rassool, M

AU - Sanders, K

AU - Solanki, R

AU - Squire, SB

AU - Torrea, G

AU - Tsogt, B

AU - Tudor, E

AU - Van Deun, A

AU - Rusen, ID

N1 - FTX; DOAJ; (CC BY)

PY - 2022

Y1 - 2022

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=itm_wosliteitg&SrcAuth=WosAPI&KeyUT=WOS:000923435200020&DestLinkType=FullRecord&DestApp=WOS_CPL

UR - http://10.1016/S0140-6736(22)02078-5

U2 - 10.1016/S0140-6736(22)02078-5

DO - 10.1016/S0140-6736(22)02078-5

M3 - A1: Web of Science-article

C2 - 36368336

SN - 0140-6736

VL - 400

SP - 1858

EP - 1868

JO - Lancet

JF - Lancet

IS - 10366

ER -

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Access to Document

Other files and links

Cite this